We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
- Authors
Joensuu, H.; De Braud, F.; Grignagni, G.; De Pas, T.; Spitalieri, G.; Coco, P.; Spreafico, C.; Boselli, S.; Toffalorio, F.; Bono, P.; Jalava, T.; Kappeler, C.; Aglietta, M.; Laurent, D.; Casali, P. G.
- Abstract
<bold>Background: </bold>Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) resistant to imatinib or both imatinib and sunitinib.<bold>Patients and Methods: </bold>Forty-five patients whose metastatic GIST had progressed on imatinib were enrolled. Nineteen (42.2%) patients had received also prior sunitinib. Vatalanib 1250 mg was administered orally daily.<bold>Results: </bold>Eighteen patients (40.0%; 95% confidence interval (CI), 25.7-54.3%) had clinical benefit including 2 (4.4%) confirmed partial remissions (PR; duration, 9.6 and 39.4 months) and 16 (35.6%) stabilised diseases (SDs; median duration, 12.5 months; range, 6.0-35.6+ months). Twelve (46.2%) out of the 26 patients who had received prior imatinib only achieved either PR or SD compared with 6 (31.6%, all SDs) out of the 19 patients who had received prior imatinib and sunitinib (P=0.324). The median time to progression was 5.8 months (95% CI, 2.9-9.5 months) in the subset without prior sunitinib and 3.2 (95% CI, 2.1-6.0) months among those with prior imatinib and sunitinib (P=0.992). Vatalanib was generally well tolerated.<bold>Conclusion: </bold>Vatalanib is active despite its narrow kinome interaction spectrum in patients diagnosed with imatinib-resistant GIST or with imatinib and sunitinib-resistant GIST.
- Subjects
GASTROINTESTINAL stromal tumors; ENDOTHELIAL growth factors; DRUG resistance in cancer cells; AMINOTRANSFERASES; DOXORUBICIN; THROMBOCYTOPENIA; DRUG efficacy; GENETIC mutation; THERAPEUTIC use of antineoplastic agents; PYRIDINE; RESEARCH; INDOLE compounds; CLINICAL trials; HETEROCYCLIC compounds; PROTEIN kinase inhibitors; PROGNOSIS; MEDICAL cooperation; GASTROINTESTINAL tumors; BENZAMIDE
- Publication
British Journal of Cancer, 2011, Vol 104, Issue 11, p1686
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/bjc.2011.151